Research programme: adoptive T-cell therapy - Medigene

Drug Profile

Research programme: adoptive T-cell therapy - Medigene

Alternative Names: Immunotherapy-Medigene Immunotherapies; MDG 1011; T-cell receptor T4.8-1-29; TCR-modified T-cells-Medigene Immunotherapies

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helmholtz Zentrum Munchen; Max Delbruck Center for Molecular Medicine
  • Developer Medigene Immunotherapies
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Aug 2017 Medigene in collaboration with Delbruck Center for Molecular Medicine plans an investigator-initiated trial for Multiple myeloma
  • 10 Jul 2017 Medigene AG files a clinical trial authorization application with the Paul-Ehrlich-Institute (PEI) in Germany for Haematological malignancies
  • 05 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 108th Annual meeting of Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top